February 2011 in “Annales de dermatologie et de vénéréologie” Tofacitinib shows promise for treating severe alopecia areata with good safety and effectiveness.
January 2024 in “American journal of clinical dermatology” Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.
January 2018 in “Journal of the American Academy of Dermatology” More extensive trials are needed to understand tofacitinib's role in treating severe hair loss.
8 citations
,
April 2019 in “Dermatologic Therapy” Tretinoin boosts minoxidil's effect on hair loss by increasing enzyme activity.
January 2022 in “SSRN Electronic Journal” Gemcitabine and Disitamab Vedotin effectively and safely reduced bladder cancer in a patient.
1 citations
,
January 2020 in “Surgical & Cosmetic Dermatology” Combining oral minoxidil with JAK inhibitors helps regrow hair in severe alopecia areata cases.
5 citations
,
August 2002 in “Veterinary Dermatology” Combining terbinafine and mitotane effectively treated a schnauzer's skin infection and hormone disorder.
1 citations
,
April 2017 in “Journal of Investigative Dermatology” Tofacitinib may help regrow hair in severe alopecia areata, but results differ greatly between people.
May 2026 in “Journal of Neurosciences in Rural Practice” Tofacitinib may cause nerve damage in the brain, so monitor for neurological symptoms.
77 citations
,
January 1980 in “Carcinogenesis” TPA is about 50 times more effective at promoting tumors than MZ.
36 citations
,
January 2012 in “Dermatology” Stopping gefitinib improved scalp condition in a woman with lung cancer.
9 citations
,
August 2018 in “JAAD Case Reports” Tofacitinib can temporarily improve hair growth in alopecia universalis, but its effectiveness may decrease over time.
16 citations
,
September 1999 in “Journal of Investigative Dermatology Symposium Proceedings”
4 citations
,
January 2022 in “Dermatologic Therapy” Tofacitinib was found to be a safe and effective treatment for hair regrowth in patients with alopecia areata.
October 2025 in “Dermatology and Therapy” Ritlecitinib is being tested for effectiveness and safety in treating severe alopecia areata.
6 citations
,
November 2017 in “Journal of the European Academy of Dermatology and Venereology” A woman got melanoma on her scalp after anti-hair loss treatment with injections.
1 citations
,
December 2016 JAK inhibitors have therapeutic potential but pose significant risks, requiring careful monitoring.
25 citations
,
March 2017 in “International Journal of Dermatology” Ruxolitinib effectively and safely regrows hair in alopecia patients.
1 citations
,
April 2023 in “Heliyon” Disitamab vedotin and gemcitabine effectively treated bladder cancer without major side effects.
36 citations
,
January 2016 in “The journal of investigative dermatology/Journal of investigative dermatology” The document concludes that understanding genetic mutations in the PI3K-AKT-mTOR pathway can lead to better diagnosis and treatment for certain genetic skin disorders.
September 2023 in “Medicina Estética Revista Científica de la Sociedad Española de Medicina Estética (SEME)” The FDA approved Litfulo® for treating severe alopecia areata in people aged 12 and older.
November 2023 in “Journal of Cosmetic Dermatology” Tofacitinib is effective and has minor, reversible side effects for treating severe hair loss in Iran.
1 citations
,
April 2025 in “Clinical Cosmetic and Investigational Dermatology” Erlotinib can cause scalp pustules and hair loss, needing early treatment with antibiotics and steroids.
November 2025 in “Journal of Investigative Dermatology” March 2026 in “British Journal of Dermatology” Deucravacitinib did not significantly improve hair regrowth in alopecia areata patients.
May 2025 in “OPAL (Open@LaTrobe) (La Trobe University)” Linoleic acid and magnesium are key in alopecia areata progression, and tofacitinib can help by affecting their pathway.
3 citations
,
March 2016 in “Practical radiation oncology” Total skin electron therapy is an effective treatment for mycosis fungoides, balancing effectiveness and side effects.
4 citations
,
July 2023 in “Nature Medicine” The FDA approved a new Pfizer drug for hair loss in teens.
324 citations
,
May 2002 in “Oncogene” March 2026 in “Journal of Investigative Dermatology”